Neurocrine Biosciences, Inc. (LON:0K6R)
London · Delayed Price · Currency is GBP · Price in USD 137.64
-10.63 (-7.17%)
At close: Oct 29, 2025
Neurocrine Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 2,683 | 2,355 | 1,887 | 1,489 | 1,134 | 1,046 | Upgrade | |
Revenue Growth (YoY) | 19.61% | 24.81% | 26.76% | 31.34% | 8.38% | 32.71% | Upgrade |
Cost of Revenue | 986.9 | 765.1 | 604.7 | 487 | 342.4 | 285.1 | Upgrade |
Gross Profit | 1,696 | 1,590 | 1,282 | 1,002 | 791.1 | 760.8 | Upgrade |
Selling, General & Admin | 1,156 | 1,007 | 887.6 | 752.7 | 583.3 | 433.3 | Upgrade |
Operating Expenses | 1,156 | 1,007 | 887.6 | 752.7 | 583.3 | 433.3 | Upgrade |
Operating Income | 540.3 | 583 | 394.8 | 249 | 207.8 | 327.5 | Upgrade |
Interest Expense | - | - | - | - | -25.8 | -32.8 | Upgrade |
Interest & Investment Income | 87 | 91 | 52.8 | 4.1 | 3.8 | 12.6 | Upgrade |
EBT Excluding Unusual Items | 627.3 | 674 | 447.6 | 253.1 | 185.8 | 307.3 | Upgrade |
Gain (Loss) on Sale of Investments | -8.6 | -37.1 | 28.4 | 30.8 | 20.9 | -17.7 | Upgrade |
Other Unusual Items | - | -138.4 | - | -70 | - | -18.4 | Upgrade |
Pretax Income | 628.6 | 486 | 332.1 | 213.9 | 101.4 | 106.7 | Upgrade |
Income Tax Expense | 200.6 | 144.7 | 82.4 | 59.4 | 11.8 | -300.6 | Upgrade |
Net Income | 428 | 341.3 | 249.7 | 154.5 | 89.6 | 407.3 | Upgrade |
Net Income to Common | 428 | 341.3 | 249.7 | 154.5 | 89.6 | 407.3 | Upgrade |
Net Income Growth | 10.91% | 36.68% | 61.62% | 72.43% | -78.00% | 1000.81% | Upgrade |
Shares Outstanding (Basic) | 99 | 100 | 98 | 96 | 95 | 93 | Upgrade |
Shares Outstanding (Diluted) | 102 | 104 | 101 | 99 | 98 | 98 | Upgrade |
Shares Change (YoY) | -1.30% | 2.67% | 2.12% | 1.02% | 0.10% | 2.19% | Upgrade |
EPS (Basic) | 4.30 | 3.40 | 2.56 | 1.61 | 0.95 | 4.37 | Upgrade |
EPS (Diluted) | 4.19 | 3.29 | 2.47 | 1.56 | 0.92 | 4.16 | Upgrade |
EPS Growth | 12.44% | 33.20% | 58.33% | 69.56% | -77.89% | 966.67% | Upgrade |
Free Cash Flow | 593.1 | 557.2 | 361.6 | 322.9 | 233.1 | 217.6 | Upgrade |
Free Cash Flow Per Share | 5.80 | 5.37 | 3.58 | 3.27 | 2.38 | 2.23 | Upgrade |
Gross Margin | 63.21% | 67.52% | 67.96% | 67.29% | 69.79% | 72.74% | Upgrade |
Operating Margin | 20.14% | 24.75% | 20.92% | 16.73% | 18.33% | 31.31% | Upgrade |
Profit Margin | 15.95% | 14.49% | 13.23% | 10.38% | 7.90% | 38.94% | Upgrade |
Free Cash Flow Margin | 22.11% | 23.66% | 19.16% | 21.69% | 20.57% | 20.80% | Upgrade |
EBITDA | 570 | 610.1 | 416.1 | 264.6 | 218.7 | 336.1 | Upgrade |
EBITDA Margin | 21.25% | 25.90% | 22.05% | 17.77% | 19.29% | 32.14% | Upgrade |
D&A For EBITDA | 29.7 | 27.1 | 21.3 | 15.6 | 10.9 | 8.6 | Upgrade |
EBIT | 540.3 | 583 | 394.8 | 249 | 207.8 | 327.5 | Upgrade |
EBIT Margin | 20.14% | 24.75% | 20.92% | 16.73% | 18.33% | 31.31% | Upgrade |
Effective Tax Rate | 31.91% | 29.77% | 24.81% | 27.77% | 11.64% | - | Upgrade |
Revenue as Reported | 2,683 | 2,355 | 1,887 | 1,489 | 1,134 | 1,046 | Upgrade |
Advertising Expenses | - | 191 | 159.9 | 149.7 | 139.8 | 64.8 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.